Related references
Note: Only part of the references are listed.European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
Marko Babjuk et al.
EUROPEAN UROLOGY (2022)
Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis
Francesco Del Giudice et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Safety and efficacy of various strains of bacille Calmette-Guerin in the treatment of bladder tumours in standard clinical practice
M. Unda-Urzai et al.
ACTAS UROLOGICAS ESPANOLAS (2018)
Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials
Yongjun Quan et al.
MEDICINE (2017)
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
Sam S. Chang et al.
JOURNAL OF UROLOGY (2016)
Evaluation of adverse events caused by intravesical BCG instillations: Has the strain used a potential implication?
S. Holz et al.
PROGRES EN UROLOGIE (2016)
Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients
Paolo Gontero et al.
EUROPEAN UROLOGY (2015)
Bacillus Calmette-Guerin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy
Cyrill A. Rentsch et al.
EUROPEAN UROLOGY (2014)
Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)
Naim B. Farah et al.
BMC UROLOGY (2014)
A Prospective Comparative Study of Intravesical Bacillus Calmette-Guerin Therapy with the Tokyo or Connaught Strain for Nonmuscle Invasive Bladder Cancer
Atsushi Sengiku et al.
JOURNAL OF UROLOGY (2013)
Prognostic Significance in Substaging of T1 Urinary Bladder Urothelial Carcinoma on Transurethral Resection
Wei-Chin Chang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Jesus Fernandez-Gomez et al.
JOURNAL OF UROLOGY (2009)
Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials
Rui Fa Han et al.
UROLOGY (2006)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials
MD Shelley et al.
BJU INTERNATIONAL (2004)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2002)
A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
MD Shelley et al.
BJU INTERNATIONAL (2001)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
DL Lamm et al.
JOURNAL OF UROLOGY (2000)
Share Paper
